| 摘要 |
The invention relates to compounds represented by Structural Formula I, which can bind to CCR9 receptors and block the binding of a ligand (e.g., TECK) to the receptors. The invention also relates to a method of inhibiting a function of CCR9, and to the use compounds represented by Structural Formula I in research, therapeutic, prophylactic and diagnostic methods. |
| 主权项 |
1. A compound represented by the following structural formula: or a pharmaceutically acceptable salt thereof, wherein: Y is C═O, S(O), or S(O)2; X1, X2, and X3 are each independently N or CR, provided that at least one of X1, X2, or X3 is CR; R, for each occurrence, and R1 are each independently H, an aliphatic group, haloalkyl, aryl, arylalkyl, alkoxy, cycloalkoxy, haloalkoxy, aryloxy, arylalkoxy, alkylthio, halo, nitro, cyano, hydroxy, NR11CO2R12, C(O)N(R11)2, C(O)R12, CO2R12, OC(O)N(R11)2, OC(O)R12, N(R11)2, or NR11C(O)R12; wherein R11, for each occurrence is, independently, H or an aliphatic group, and R12 is an aliphatic group; R6 is H, an aliphatic carbonyl group, or an aliphatic ester; Ar1 is a substituted or unsubstituted group selected from pyridyl, N-oxido pyridyl, pyrimidinyl, and pyrazinyl; and Ar2 is a substituted or unsubstituted aryl group or a substituted or unsubstituted heteroaryl group. |
